Search Bar & Filters
Found 114 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness of Mulligan Mobilization Technique compared to proprioceptive exercises for treating adults aged 40 and above with mild to moderate knee osteoarthritis, classified as Grades 2 and 3 on the Kellgren and Lawrence scale. The study aims to assess these treatments over a 10-week period, focusing on pain levels, movement, functional activities, balance, and quality of life improvements. Participants are selected based on clinical diagnosis and mobility ability without assistive devices. The study involves three groups one receiving proprioceptive exercises designed to improve balance and joint position sense, another receiving Mulligan Mobilization Technique, a manual therapy to improve joint mobility, and a control group undergoing traditional physical therapy. Each participant receives 30 treatment sessions over 10 weeks, with three sessions per week lasting 40 to 60 minutes each. Treatments are delivered by trained physical therapists, and assessments occur at the start and end of the treatment period. Participants will complete questionnaires and undergo evaluations measuring pain intensity, range of motion, functional status, and balance using tools like the Numeric Pain Rating Scale, Universal Goniometer, Knee Injury and Osteoarthritis Outcome Score, and Berg Balance Scale. Quality of life is also assessed using the SF-36 questionnaire. The study follows a double-blind, randomized design to ensure unbiased results. Confidentiality is maintained, and participants may withdraw at any time without penalty.
Actively Recruiting
Healthy Volunteer
Researchers are observing patients at preventive cardiology clinics to better understand how cardiovascular risk assessment tools can be used most effectively. The study aims to explore how these tools influence the risk of cardiovascular disease CVD and related outcomes, focusing on both primary and secondary prevention. This ongoing research collects data to help clinicians develop personalized, effective treatment plans by combining individual risk factors. The study involves adult patients attending the National Institute of Cardiovascular Diseases NICVD in Karachi, Pakistan. It gathers detailed information such as demographic data, physical exams, clinical history, risk modifications, laboratory tests, and risk scores like the ASCVD and WHO Cardiovascular Risk scores. These assessments are recorded at the first visit and during follow-ups to track changes over time. Participants provide verbal consent and are followed over a long period, with data collection continuing regularly. Researchers analyze this information to measure cardiovascular risk over ten years, changes in risk levels, and cardiovascular-related deaths. The study uses structured questionnaires and statistical methods to evaluate the findings, aiming to contribute valuable insights into cardiovascular disease prevention and management.
Actively Recruiting
Researchers are conducting an international, multicenter, randomized, controlled, open-label Phase III trial to evaluate the effectiveness and safety of libevitug in people with chronic Hepatitis Delta Virus HDV infection. The study focuses on participants aged 12 to 70 years who have a history of chronic HDV infection and specific liver enzyme levels. Participants will be assigned to one of three groups one group receiving libevitug at 20 mgkg every two weeks through intravenous infusion for 96 weeks another group receiving a lower dose of 10 mgkg on the same schedule and a control group observed for 48 weeks before then receiving the 20 mgkg libevitug dosage for the following 48 weeks. This setup allows comparison of different dosing and delayed treatment effects. Throughout the study, participants will undergo regular evaluations including liver function tests, viral load measurements, and liver stiffness assessments. The primary outcome is the proportion of participants achieving a significant reduction in HDV RNA and normalization of liver enzymes at week 48. Additional outcomes will be monitored up to week 120, including safety monitoring for adverse events. The total participation may last up to about two and a half years, with careful follow-up to assess long-term effects.
Actively Recruiting
Healthy Volunteer
Researchers are investigating the effects of vitamin D supplementation and topical fluoride treatments on people aged 12 to 45 who have vitamin D deficiency and early dental cavities called Initial Carious Lesions ICL. This trial aims to compare how these treatments influence the progression of ICL by measuring changes in the International Caries Detection and Assessment System ICDAS scores, concentrations of proteins in saliva, and the presence of cavity-causing bacteria over six months. The study is conducted as a randomized controlled trial at multiple outpatient centers. Participants are randomly assigned to one of three groups Group A receives vitamin D supplements and oral hygiene instructions Group B receives vitamin D supplements, topical fluoride application, and oral hygiene instructions and Group C, the control group with sufficient vitamin D levels, receives topical fluoride and oral hygiene instructions. Vitamin D supplements include weekly 50,000 IU doses for two months followed by daily maintenance doses of 5,000 IU for one month. Fluoride treatments involve professional application of 5% sodium fluoride gel for five minutes on affected teeth. During the six-month study, participants will have their dental health monitored through assessments of their ICDAS scores, saliva samples analyzed for protein levels using ELISA, and bacterial counts measured by PCR techniques. Researchers will also check serum vitamin D levels. Oral hygiene and diet counseling are provided. The study evaluates the progression of initial cavities, changes in saliva biomarkers, and oral bacteria to understand how these interventions impact dental caries management.
Actively Recruiting
Researchers are conducting a Phase 3, global, randomized, open-label trial to compare the effects of brelovitug BJT-778 and bulevirtide for treating chronic hepatitis delta infection CHD. The study aims to evaluate the long-term effectiveness of brelovitug compared to bulevirtide in patients with chronic HDV infection. This trial involves approximately 172 participants assigned to different treatment arms. Participants are randomized 31 into two groups. One group receives brelovitug 300 mg by subcutaneous injection once weekly for 96 weeks. The other group receives bulevirtide 2 mg by subcutaneous injection once daily for 48 weeks, followed by brelovitug 300 mg once weekly for the next 48 weeks. This design allows comparison of both treatments and their sequences over nearly two years. Throughout the study, participants will undergo regular monitoring including blood tests to measure HDV RNA levels, liver enzyme normalization, and liver stiffness. Safety is assessed by tracking treatment-emergent adverse events and treatment discontinuations due to adverse events. Quality of life and liver disease progression are also evaluated. The primary outcome measures the percentage of participants achieving a virologic response and ALT normalization at 48 weeks, with long-term follow-up extending up to 96 weeks and beyond.
Actively Recruiting
Researchers are evaluating the effect of adenosine pre-medication on the occurrence of slow flow or no-reflow after primary percutaneous coronary intervention PCI in adults with ST-segment elevation myocardial infarction STEMI. This study is a randomized controlled trial involving 1,148 patients, designed to assess whether giving adenosine before PCI can improve heart muscle blood flow and reduce complications associated with inadequate myocardial perfusion. Participants will be randomly assigned to one of two groups one group will receive intracoronary adenosine before PCI along with standard pharmacological treatment, while the control group will receive only standard care during PCI. The adenosine dose is 2 mg for the left coronary artery and 1 mg for the right coronary artery, diluted in 20 mL normal saline, administered immediately before the procedure. The study will take place over 12 months at multiple centers. During the study, researchers will collect baseline and procedural data, monitoring the incidence of slow flow or no-reflow using TIMI flow grades during the PCI procedure. They will also assess myocardial perfusion through the Myocardial Blush Grade. Safety will be monitored for potential side effects such as transient bradycardia or heart block. Statistical analysis will evaluate the outcomes, and participants will be followed until the study concludes at the end of 2026.
Actively Recruiting
Researchers are comparing the effects of xylometazoline nasal drops and adrenaline nasal packing on nasal bleeding during nasotracheal intubation in participants undergoing elective oromaxillofacial surgeries. The trial aims to determine which of these two treatments better reduces nasal bleeding during the procedure. This study includes participants aged 18 to 60 years with specific health criteria to ensure safety and accuracy. Participants are randomly assigned to one of two groups. One group receives 0.1% xylometazoline nasal drops, administered as 3 to 5 drops in the selected nostril 15 minutes before surgery. The other group receives adrenaline nasal packing, where a gauze soaked in adrenaline is placed inside the nostril 15 minutes before surgery and removed after 7 to 10 minutes. Both groups undergo nasotracheal intubation under general anesthesia with careful monitoring. Throughout the study, participants will have vital signs monitored, including blood pressure, heart rate, ECG, and oxygen saturation. An experienced anesthesiologist will perform the procedures and record the incidence and severity of nasal bleeding during intubation and extubation. Data will be analyzed to compare bleeding outcomes between groups while considering factors like age, gender, and medical history. Participation lasts through the surgical procedure and immediate recovery monitoring.
Actively Recruiting
Healthy Volunteer
Researchers are collecting eye images from 1000 participants aged 50 and older, including those with healthy eyes and those diagnosed with any stage of Age-Related Macular Degeneration AMD. The goal is to develop a diverse dataset to support the creation of an Artificial Intelligence AI screening tool for AMD. This tool aims to help detect early AMD in primary care and optometry settings to reduce vision loss and treatment burden. Participants will undergo a single retinal imaging session of both eyes, which includes color fundus photography before and after pupil dilation and macular spectral domain-optical coherence tomography SD-OCT. The study also collects detailed patient history, physical exam data, visual acuity measurements, and AMD classification using the Beckman scale. The dataset will be balanced by age, sex, and AMD severity to ensure diversity. During the study, participants provide demographic information, smoking and family history, height and weight measurements, and undergo eye imaging and vision tests. Researchers will classify AMD stage and track geographic location of participants. This observational study does not involve treatment but focuses on gathering data to support AI model development. The study runs from May 2025 to June 2027 across up to 25 international sites.
Actively Recruiting
Levator scapulae syndrome LSS is a common musculoskeletal condition causing persistent neck and shoulder pain, especially among workers with prolonged static postures and repetitive movements, such as cosmetics professionals and manual laborers. This trial evaluates two treatmentsPositional Release Technique and Dry Needling Therapyto improve pain and function in people with LSS. Participants will be randomly assigned to one of two groups the experimental group receiving Positional Release Technique on the levator scapulae muscle along with neck strengthening exercises, and the control group receiving Dry Needling treatment plus the same exercises. Treatments are delivered based on specific techniques involving muscle relaxation or needle insertion, respectively. Both groups undergo treatment over a four-week period. Throughout the study, participants will be assessed at baseline and after four weeks for pain using the Visual Analogue Scale, muscle strength by the Oxford Scale, neck range of motion with Cervical Range of Motion measurements, daily disability using the Neck Disability Index, and quality of life through the EuroQol-5D questionnaire. The study includes functional activity evaluations and a global rating of change to track progress. The trial is sponsored by the University of Karachi and is expected to complete by September 2027.
Actively Recruiting
This research aims to evaluate whether showing an animated video of the procedure can reduce pain and anxiety in children undergoing pin removal after supracondylar fracture fixation. The study focuses on pediatric patients aged 4 to 12 years who have had K-wire fixation for these fractures. Pain and anxiety related to pin removal can be distressing, and this study investigates a distraction method to ease these symptoms. Participants will be randomly assigned to one of two groups. One group will watch an animated video of the pin removal procedure during the treatment, while the other group will undergo pin removal without the video. The procedure involves removal of the K-wire used to fix the fracture. The study uses a randomized, quadruple-masked design to compare outcomes between these two approaches. Childrens pain and anxiety will be measured using several scales, including the Wong Baker Pain Scale, Childrens Hospital of Eastern Ontario Pain Scale, Childrens Anxiety Meter-State, and Short State Trait Anxiety Inventory Scale. These assessments will be done before, during, and 60 minutes after the procedure. The study will monitor changes in pain and anxiety levels to determine the impact of the animated video. The trial runs from October 2025 to January 2026 and is sponsored by Liaquat National Hospital & Medical College.
1-10 of 114
1